Search

Located in the heart of biomedical innovation in Madrid, and with an investment of over 35 million euros and 18,000 m² of space dedicated to health research as well as scientific, social, and outreach

Meet our new member, BioDuro. We spoke with Ricardo Inacio, Executive Director | Business Development EU.

At AseBio, we strongly support the proposals put forward by the Minister of Industry and Tourism, which not only reflect the work and demands we have been advocating for, but also respond to many of

New U.S. investment bank joins, bringing total coverage to ten analysts.

It aims to turn health data into a strategic asset to improve healthcare, accelerate innovation in health technologies and empower European patients.

AseBio has played a leading role as the head of Work Package 3, “Testing and Implementation,” one of the core pillars of the project.

Meet Maieutics Research Solutions, our new member. We talk with Lander Ezequiel Senderowicz, Operational Manager

New “Decision to grant” communications in Canada and Israel. For the treatment of aggression and social withdrawal

In 2024, the Parc Científic de Barcelona (PCB) reached full occupancy of its facilities and is preparing for a forthcoming expansion with two key projects: the refurbishment of the CUB building, which

The report prepared by AseBio as an initiative of its Sustainability Committee identifies 587 solutions focused on identifying and adopting new ways of production and consumption that respect the

The initiative focuses on the transformation of this biomass into animal feed, functional additives, environmentally friendly packaging, and biogas

The CIBER Cancer Area (CIBERONC) is developing advanced cellular therapies targeting pediatric sarcomas, with a special focus on Ewing sarcoma.

Meet our new member Inbistra. We spoke with Ignacio Sancho-Martinez CEO y co-fundadorr

Meet IMCD, our new Ally. We spoke with Lander Elkoro, Market Manager Formulation & Biopharma Iberia.

Trimerbody Pharma, a clinical-stage biopharmaceutical company developing proprietary therapeutic antibodies called Trimerbodies against cancer, announces that it has changed its name from Leadartis